J. B. Chemicals & Pharmaceuticals Limited Share Price
Equities
JBCHEPHARM
INE572A01036
Pharmaceuticals
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1,978.00 INR | -1.03% |
|
+1.68% | +8.65% |
| 10/03 | J. B. Chemicals & Pharmaceuticals Limited Announces Management Cessations | CI |
| 05/02 | JB Chemicals says Narayan Saraf resigns as CFO | RE |
| Capitalization | 32TCr 344.7Cr 292.13Cr 269.09Cr 254.03Cr 474.32Cr 482.9Cr 3.16TCr 1.24TCr 15TCr 1.29TCr 1.27TCr 55TCr | P/E ratio 2026 * |
39.5x | P/E ratio 2027 * | 33.2x |
|---|---|---|---|---|---|
| Enterprise value | 31TCr 337.31Cr 285.87Cr 263.32Cr 248.59Cr 464.15Cr 472.55Cr 3.1TCr 1.21TCr 15TCr 1.27TCr 1.24TCr 54TCr | EV / Sales 2026 * |
7.31x | EV / Sales 2027 * | 6.41x |
| Free-Float |
45.74% | Yield 2026 * |
0.79% | Yield 2027 * | 0.86% |
Last Transcript: J. B. Chemicals & Pharmaceuticals Limited
| 1 day | -1.03% | ||
| 1 week | +1.68% | ||
| Current month | -4.13% | ||
| 1 month | -5.30% | ||
| 3 months | +4.02% | ||
| 6 months | +18.72% | ||
| Current year | +8.65% |
| 1 week | 1,938.6 |  | 2,025.95 |
| 1 month | 1,866.55 | | 2,195 |
| Current year | 1,777.05 | | 2,195 |
| 1 year | 1,495 | | 2,195 |
| 3 years | 914.65 | | 2,195 |
| 5 years | 603.18 | | 2,195 |
| 10 years | 115.5 | | 2,195 |
| Manager | Title | Age | Since |
|---|---|---|---|
Sujay Rajhans
CTO | Chief Tech/Sci/R&D Officer | 49 | 30/03/2021 |
| Chief Administrative Officer | 59 | 15/09/2016 | |
Suresh Bhise
CTO | Chief Tech/Sci/R&D Officer | 60 | 01/06/2014 |
| Director | Title | Age | Since |
|---|---|---|---|
Sumit Bose
BRD | Director/Board Member | 71 | 31/08/2020 |
| Chairman | 79 | 05/07/2024 | |
| Director/Board Member | 69 | 14/05/2025 |
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -1.03% | +1.68% | +24.33% | +84.76% | 344.7Cr | |
| -0.76% | -0.92% | +22.29% | +146.18% | 83TCr | |
| +0.90% | +0.71% | +55.55% | +44.78% | 58TCr | |
| +1.84% | +1.88% | +17.40% | +30.12% | 37TCr | |
| +1.28% | +1.38% | +25.39% | +13.94% | 33TCr | |
| +0.56% | -1.24% | +46.19% | +27.10% | 31TCr | |
| -0.16% | +0.57% | +51.52% | +4.03% | 30TCr | |
| +0.10% | -0.45% | +33.75% | +36.94% | 29TCr | |
| +0.32% | +3.22% | +19.40% | +40.38% | 19TCr | |
| +1.02% | +1.19% | +31.88% | +69.22% | 17TCr | |
| Average | +0.28% | +0.76% | +32.77% | +49.74% | 33.73TCr | |
| Weighted average by Cap. | +0.45% | +0.29% | +33.88% | +60.15% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 4.3TCr 46Cr 39Cr 36Cr 34Cr 64Cr 65Cr 423.67Cr 165.8Cr 2.06TCr 173.18Cr 169.52Cr 7.33TCr | 4.84TCr 52Cr 44Cr 41Cr 38Cr 72Cr 73Cr 477.28Cr 186.78Cr 2.33TCr 195.1Cr 190.98Cr 8.26TCr |
| Net income | 786.58Cr 8.45Cr 7.16Cr 6.6Cr 6.23Cr 12Cr 12Cr 78Cr 30Cr 377.88Cr 32Cr 31Cr 1.34TCr | 938.26Cr 10Cr 8.54Cr 7.87Cr 7.43Cr 14Cr 14Cr 93Cr 36Cr 450.74Cr 38Cr 37Cr 1.6TCr |
| Net Debt | -687.9Cr -7.39Cr -6.26Cr -5.77Cr -5.45Cr -10Cr -10Cr -68Cr -27Cr -330.47Cr -28Cr -27Cr -1.17TCr | -1.07TCr -11Cr -9.73Cr -8.96Cr -8.46Cr -16Cr -16Cr -105.4Cr -41Cr -513.5Cr -43Cr -42Cr -1.82TCr |
| Date | Price | Change | Volume |
|---|---|---|---|
| 15/26/15 | 1,978.00 ₹ | -1.03% | 4,467 |
| 13/26/13 | 1,998.65 ₹ | -0.25% | 4,393 |
| 10/26/10 | 2,003.75 ₹ | +1.69% | 3,396 |
| 09/26/09 | 1,970.50 ₹ | +1.29% | 3,349 |
| 08/26/08 | 1,945.40 ₹ | -0.80% | 5,502 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- JBCHEPHARM Stock
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition